Literature DB >> 23404506

EP2 receptor signaling pathways regulate classical activation of microglia.

Yi Quan1, Jianxiong Jiang, Ray Dingledine.   

Abstract

Activation of EP2 receptors by prostaglandin E2 (PGE2) promotes brain inflammation in neurodegenerative diseases, but the pathways responsible are unclear. EP2 receptors couple to Gαs and increase cAMP, which associates with protein kinase A (PKA) and cAMP-regulated guanine nucleotide exchange factors (Epacs). Here, we studied EP2 function and its signaling pathways in rat microglia in their resting state or undergoing classical activation in vitro following treatment with low concentrations of lipopolysaccharide and interferon-γ. Real time PCR showed that PGE2 had no effect on expression of CXCL10, TGF-β1, and IL-11 and exacerbated the rapid up-regulation of mRNAs encoding cyclooxygenase-2, inducible NOS, IL-6, and IL-1β but blunted the production of mRNAs encoding TNF-α, IL-10, CCL3, and CCL4. These effects were mimicked fully by the EP2 agonist butaprost but only weakly by the EP1/EP3 agonist 17-phenyl trinor PGE2 or the EP4 agonist CAY10598 and not at all by the EP3/EP1 agonist sulprostone and confirmed by protein measurements of cyclooxygenase-2, IL-6, IL-10, and TNF-α. In resting microglia, butaprost induced cAMP formation and altered the mRNA expression of inflammatory mediators, but protein expression was unchanged. The PKA inhibitor H89 had little or no effect on inflammatory mediators modulated by EP2, whereas the Epac activator 8-(4-chlorophenylthio)-2'-O-methyladenosine 3',5'-cyclic monophosphate acetoxymethyl ester mimicked all butaprost effects. These results indicate that EP2 activation plays a complex immune regulatory role during classical activation of microglia and that Epac pathways are prominent in this role.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404506      PMCID: PMC3611000          DOI: 10.1074/jbc.M113.455816

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

Review 1.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

2.  Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A.

Authors:  Alexander C Zambon; Lingzhi Zhang; Simon Minovitsky; Joan R Kanter; Shyam Prabhakar; Nathan Salomonis; Karen Vranizan; Inna Dubchak; Bruce R Conklin; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

Review 3.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

4.  Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production.

Authors:  A O Caggiano; R P Kraig
Journal:  J Neurochem       Date:  1999-02       Impact factor: 5.372

5.  Impaired inflammatory response and increased oxidative stress and neurodegeneration after brain injury in interleukin-6-deficient mice.

Authors:  M Penkowa; M Giralt; J Carrasco; H Hadberg; J Hidalgo
Journal:  Glia       Date:  2000-12       Impact factor: 7.452

6.  5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP.

Authors:  Haijun Chen; Tamara Tsalkova; Fang C Mei; Yaohua Hu; Xiaodong Cheng; Jia Zhou
Journal:  Bioorg Med Chem Lett       Date:  2012-04-26       Impact factor: 2.823

7.  Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.

Authors:  Leila Dargahi; Shiva Nasiraei-Moghadam; Azadeh Abdi; Leila Khalaj; Fatemeh Moradi; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2010-06-12       Impact factor: 3.444

Review 8.  Cyclic AMP: master regulator of innate immune cell function.

Authors:  Carlos H Serezani; Megan N Ballinger; David M Aronoff; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2008-03-06       Impact factor: 6.914

9.  Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein.

Authors:  Jinghua Jin; Feng-Shiun Shie; Jun Liu; Yan Wang; Jeanne Davis; Aimee M Schantz; Kathleen S Montine; Thomas J Montine; Jing Zhang
Journal:  J Neuroinflammation       Date:  2007-01-04       Impact factor: 8.322

10.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Authors:  Rosario Sánchez-Pernaute; Andrew Ferree; Oliver Cooper; Meixiang Yu; Anna-Liisa Brownell; Ole Isacson
Journal:  J Neuroinflammation       Date:  2004-05-17       Impact factor: 8.322

View more
  61 in total

1.  Neurotoxicity to dopamine neurons after the serial exposure to alcohol and methamphetamine: Protection by COX-2 antagonism.

Authors:  Amanda L Blaker; Eric A Rodriguez; Bryan K Yamamoto
Journal:  Brain Behav Immun       Date:  2019-06-20       Impact factor: 7.217

2.  Neuroprotective role of prostaglandin PGE2 EP2 receptor in hemin-mediated toxicity.

Authors:  Shekher Mohan; Shuh Narumiya; Sylvain Doré
Journal:  Neurotoxicology       Date:  2014-11-13       Impact factor: 4.294

Review 3.  A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition.

Authors:  Asheebo Rojas; Thota Ganesh; Wenyi Wang; Jennifer Wang; Raymond Dingledine
Journal:  Neurobiol Dis       Date:  2019-02-25       Impact factor: 5.996

4.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.

Authors:  Jianxiong Jiang; Ying Yu; Erika Reime Kinjo; Yifeng Du; Hoang Phuong Nguyen; Ray Dingledine
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

5.  The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus.

Authors:  Asheebo Rojas; Paoula Gueorguieva; Nadia Lelutiu; Yi Quan; Renee Shaw; Raymond Dingledine
Journal:  Neurobiol Dis       Date:  2014-06-19       Impact factor: 5.996

6.  StEPing "EP2" to Prevent Status Epilepticus-Induced Mortality and Inflammation.

Authors:  Pallavi Bhuyan; Manisha Patel
Journal:  Epilepsy Curr       Date:  2014-01       Impact factor: 7.500

Review 7.  Cyclooxygenase-2 in epilepsy.

Authors:  Asheebo Rojas; Jianxiong Jiang; Thota Ganesh; Myung-Soon Yang; Nadia Lelutiu; Paoula Gueorguieva; Raymond Dingledine
Journal:  Epilepsia       Date:  2013-11-08       Impact factor: 5.864

Review 8.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

9.  Development of second generation EP2 antagonists with high selectivity.

Authors:  Thota Ganesh; Jianxiong Jiang; Ray Dingledine
Journal:  Eur J Med Chem       Date:  2014-06-03       Impact factor: 6.514

10.  Cerebroprotection by the neuronal PGE2 receptor EP2 after intracerebral hemorrhage in middle-aged mice.

Authors:  He Wu; Tao Wu; Xiaoning Han; Jieru Wan; Chao Jiang; Wenwu Chen; Hong Lu; Qingwu Yang; Jian Wang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.